Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (491-500 of 527) with videos related to

Pageof 53
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Clinical and Molecular Hepatology|March 17, 2025
Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatmentRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International|March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryTe-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in TaiwanSzu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International|February 28, 2024
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantationDong-Sik Kim, Young-In Yoon, Beom Kyung Kim, et al.
Hepatology International|January 4, 2021
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patientsMatt Liu, Tai-Chung Tseng, Dae Won Jun, et al.
Journal of Hepatology|November 20, 2023
Global survey of stigma among physicians and patients with nonalcoholic fatty liver diseaseZobair M Younossi, Saleh A Alqahtani, Khalid Alswat, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registryTyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy|April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in TaiwanChun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Pageof 53

Showing results (491-500 of 527) with videos related to

Sort By:
Pageof 53
Journal of the Formosan Medical Association = Taiwan Yi Zhi|June 10, 2025
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, et al.
Clinical and Molecular Hepatology|March 17, 2025
Impact of components of metabolic syndrome on long-term outcomes of CHB with nucleos(t)ide analogue treatmentRui Huang, Dae Won Jun, Hidenori Toyoda, et al.
The Kaohsiung Journal of Medical Sciences|June 20, 2025
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in TaiwanSzu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, et al.
Hepatology International|March 27, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registryTe-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, et al.
The Kaohsiung Journal of Medical Sciences|January 20, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in TaiwanSzu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, et al.
Hepatology International|February 28, 2024
Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantationDong-Sik Kim, Young-In Yoon, Beom Kyung Kim, et al.
Hepatology International|January 4, 2021
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patientsMatt Liu, Tai-Chung Tseng, Dae Won Jun, et al.
Journal of Hepatology|November 20, 2023
Global survey of stigma among physicians and patients with nonalcoholic fatty liver diseaseZobair M Younossi, Saleh A Alqahtani, Khalid Alswat, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|August 21, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registryTyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, et al.
Infectious Diseases and Therapy|April 28, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in TaiwanChun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, et al.
Pageof 53